As shown in Figure 1, CCND2 could be a prognostic biomarker in breast cancer, kidney renal papillary cell cancer, lung cancer, ovarian cancer, pancreatic ductal adenocarcinoma, pheochromocytoma and paraganglioma, rectum adenocarcinoma, thyroid carcinoma, and uterine corpus endometrial carcinoma (P < 0.05). Here, CCND2 is linked to hereditary pheochromocytoma-paraganglioma.